Table 1 |
||||||
|
Respiratory tissue parameters under baseline conditions, during MCh infusion at a dose of 24 μg/kg/min, and their percentage changes in the different groups |
||||||
|
G (cmH2O/l) |
Change in G |
H (cmH2O/l) |
Change in H |
|||
|
|
||||||
|
Baseline |
MCh 24 μg/kg/min |
% |
Baseline |
MCh 24 μg/kg/min |
% |
|
|
|
||||||
|
CC |
866 ± 49 |
1150 ± 76* |
33 ± 5 |
2927 ± 299 |
3767 ± 334* |
31 ± 4 |
|
CS |
736 ± 42 |
968 ± 78* |
31 ± 5 |
2936 ± 167 |
3329 ± 195* |
15 ± 6 |
|
VIP |
735 ± 33 |
991 ± 49* |
37 ± 10 |
2589 ± 258 |
3139 ± 231* |
24 ± 5 |
|
ILO |
802 ± 84 |
930 ± 65* |
21 ± 9 |
2972 ± 397 |
3061 ± 147 |
10 ± 10 |
|
SIL |
964 ± 45 |
1159 ± 50* |
21 ± 6 |
3240 ± 281 |
3741 ± 278* |
16 ± 3 |
|
TEZ |
727 ± 34 |
911 ± 58* |
25 ± 3 |
2370 ± 156 |
3001 ± 232* |
26 ± 2 |
|
|
||||||
|
CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan. *: p < 0.05 vs. the value obtained under baseline conditions within a group. |
||||||
|
Habre et al. Respiratory Research 2011 12:58 doi:10.1186/1465-9921-12-58 |
||||||
